Prostaglandins and n-3 polyunsaturated fatty acids in the regulation of the hypothalamic-pituitary axis

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 91, Issue 6, 2014, Pages 277-287

  Shewchuk, Brian M ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Hypothalamus; N 3 PUFA; Neuroinflammation; Obesity; Pituitary; Prostaglandin

Indexed keywords

ARGIPRESSIN; CORTICOTROPIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450; FOLLITROPIN; G PROTEIN COUPLED RECEPTOR; GROWTH HORMONE; INSULIN; LEPTIN; LIPOXYGENASE; LUTEINIZING HORMONE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; MELATONIN; NITRIC OXIDE; OMEGA 3 FATTY ACID; OXYTOCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHOLIPASE A2; PROLACTIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTANOID; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE 1 PHOSPHATE; THROMBOCYTE ACTIVATING FACTOR; THYROTROPIN; TOLL LIKE RECEPTOR 4; FAT INTAKE; HYPOPHYSIS HORMONE;

BRAIN DEVELOPMENT; BRAIN METABOLISM; CELL PROLIFERATION; CHEMOTAXIS; EMBRYO GROWTH; FATTY ACID OXIDATION; FEEDBACK SYSTEM; FUNCTIONAL ANATOMY; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; NERVOUS SYSTEM INFLAMMATION; NEUROHYPOPHYSIS; OBESITY; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; BIOSYNTHESIS; DIET; FAT INTAKE; HYPOPHYSIS; HYPOTHALAMUS; INFLAMMATION; PHYSIOLOGY; SECRETION (PROCESS);

DIET; DIETARY FATS; FATTY ACIDS, OMEGA-3; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; HYPOTHALAMUS; INFLAMMATION; OBESITY; PITUITARY GLAND; PITUITARY HORMONES; PROSTAGLANDINS;

EID: 84922065645     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2014.09.005     Document Type: Article

References (192)

1. Thaler J.P., Schwartz M.W. Minireview: inflammation and obesity pathogenesis: the hypothalamus heats up. Endocrinology 2010, 151:4109-4115.
2. Orr S.K., Trepanier M.O., Bazinet R.P. n-3 Polyunsaturated fatty acids in animal models with neuroinflammation. Prostaglandins Leukot. Essent. Fatty Acids 2013, 88:97-103.
3. Robinson L.E., Buchholz A.C., Mazurak V.C. Inflammation, obesity, and fatty acid metabolism: influence of n-3 polyunsaturated fatty acids on factors contributing to metabolic syndrome. Appl. Physiol. Nutr. Metab. 2007, 32:1008-1024.
4. Treier M., Rosenfeld M.G. The hypothalamic-pituitary axis: co-development of two organs. Curr. Opin. Cell Biol. 1996, 8:833-843.
5. Murakami M. Lipid mediators in life science. Exp. Anim. 2011, 60:7-20.
6. Narumiya S., FitzGerald G.A. Genetic and pharmacological analysis of prostanoid receptor function. J. Clin. Investig. 2001, 108:25-30.
7. Sugimoto Y., Narumiya S. Prostaglandin E receptors. J. Biol. Chem. 2007, 282:11613-11617.
8. Xu H., Valenzuela N., Fai S., Figeys D., Bennett S.A. Targeted lipidomics - advances in profiling lysophosphocholine and platelet-activating factor second messengers. FEBS J. 2013, 280:5652-5667.
9. Ishii S., Nagase T., Shimizu T. Platelet-activating factor receptor. Prostaglandins Other Lipid Mediat. 2002, 68-69:599-609.
10. Tsuda M., Tozaki-Saitoh H., Inoue K. Platelet-activating factor and pain. Biol. Pharm. Bull. 2011, 34:1159-1162.
11. Yost C.C., Weyrich A.S., Zimmerman G.A. The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie 2010, 92:692-697.
12. Kihara Y., Ishii S., Kita Y., Toda A., Shimada A., Shimizu T. Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor. J. Exp. Med. 2005, 202:853-863.
13. Knowlden S., Georas S.N. The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation. J. Immunol. 2014, 192:851-857.
14. Tager A.M., LaCamera P., Shea B.S., Campanella G.S., Selman M., Zhao Z., Polosukhin V., Wain J., Karimi-Shah B.A., Kim N.D., Hart W.K., Pardo A., Blackwell T.S., Xu Y., Chun J., Luster A.D. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med. 2008, 14:45-54.
15. Pasternack S.M., von Kugelgen I., Al Aboud K., Lee Y.A., Ruschendorf F., Voss K., Hillmer A.M., Molderings G.J., Franz T., Ramirez A., Nurnberg P., Nothen M.M., Betz R.C. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat. Genet. 2008, 40:329-334.
16. Fang W., Geng X., Deng Y., Li Y., Shang E., Cen J., Lv P. Platelet activating factor induces blood brain barrier permeability alteration in vitro. J. Neuroimmunol. 2011, 230:42-47.
17. Fang W., Zhang R., Sha L., Lv P., Shang E., Han D., Wei J., Geng X., Yang Q., Li Y. Platelet activating factor induces transient blood-brain barrier opening to facilitate edaravone penetration into the brain. J. Neurochem. 2014, 128:662-671.
18. Crack P.J., Zhang M., Morganti-Kossmann M.C., Morris A.J., Wojciak J.M., Fleming J.K., Karve I., Wright D., Sashindranath M., Goldshmit Y., Conquest A., Daglas M., Johnston L.A., Medcalf R.L., Sabbadini R.A., Pebay A. Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes. J. Neuroinflamm. 2014, 11:37.
19. Kabarowski J.H., G2A LPC regulatory functions in immunity. Prostaglandins Other Lipid Mediat. 2009, 89:73-81.
20. Takabe K., Paugh S.W., Milstien S., Spiegel S. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol. Rev. 2008, 60:181-195.
21. Fyrst H., Saba J.D. An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat. Chem. Biol. 2010, 6:489-497.
22. Martin R., Sospedra M. Sphingosine-1 phosphate and central nervous system. Curr. Top. Microbiol. Immunol. 2014, 378:149-170.
23. Singh I.N., Hall E.D. Multifaceted roles of sphingosine-1-phosphate: how does this bioactive sphingolipid fit with acute neurological injury?. J. Neurosci. Res. 2008, 86:1419-1433.
24. Lamour N.F., Subramanian P., Wijesinghe D.S., Stahelin R.V., Bonventre J.V., Chalfant C.E. Ceramide 1-phosphate is required for the translocation of group IVA cytosolic phospholipase A2 and prostaglandin synthesis. J. Biol. Chem. 2009, 284:26897-26907.
25. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol. Res. 2009, 60:77-84.
26. Petrosino S., Ligresti A., Di Marzo V. Endocannabinoid chemical biology: a tool for the development of novel therapies. Curr. Opin. Chem. Biol. 2009, 13:309-320.
27. Lambert D.M., Muccioli G.G. Endocannabinoids and related N-acylethanolamines in the control of appetite and energy metabolism: emergence of new molecular players. Curr. Opin. Clin. Nutr. Metab. Care 2007, 10:735-744.
28. Bannenberg G., Serhan C.N. Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim. Biophys. Acta 2010, 1801:1260-1273.
29. Spite M. Deciphering the role of n-3 polyunsaturated fatty acid-derived lipid mediators in health and disease. Proc. Nutr. Soc. 2013, 72:441-450.
30. Serhan C.N., Clish C.B., Brannon J., Colgan S.P., Chiang N., Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 2000, 192:1197-1204.
31. Hong S., Gronert K., Devchand P.R., Moussignac R.L., Serhan C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 2003, 278:14677-14687.
32. Marcheselli V.L., Hong S., Lukiw W.J., Tian X.H., Gronert K., Musto A., Hardy M., Gimenez J.M., Chiang N., Serhan C.N., Bazan N.G. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 2003, 278:43807-43817.
33. Mukherjee P.K., Marcheselli V.L., Serhan C.N., Bazan N.G. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. USA 2004, 101:8491-8496.
34. Serhan C.N., Yang R., Martinod K., Kasuga K., Pillai P.S., Porter T.F., Oh S.F., Spite M. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med. 2009, 206:15-23.
35. Das U.N. Polyunsaturated fatty acids and their metabolites in the pathobiology of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42:122-134.
36. Farooqui A.A. Lipid mediators and their metabolism in the nucleous: implications for Alzheimer's disease. J. Alzheimers Dis. 2012, 30(Suppl 2):S163-S178.
37. Farooqui A.A. n-3 fatty acid-derived lipid mediators in the brain: new weapons against oxidative stress and inflammation. Curr. Med. Chem. 2012, 19:532-543.
38. Dunn H.C., Ager R.R., Baglietto-Vargas D., Cheng D., Kitazawa M., Cribbs D.H., Medeiros R. Restoration of Lipoxin A4 Signaling Reduces Alzheimer's Disease-Like Pathology in the 3xTg-AD Mouse Model. J. Alzheimers Dis. 2014.
39. Hawkins K.E., DeMars K.M., Singh J., Yang C., Cho H.S., Frankowski J.C., Dore S., Candelario-Jalil E. Neurovascular protection by post-ischemic intravenous injections of the lipoxin A4 receptor agonist, BML-111, in a rat model of ischemic stroke. J. Neurochem. 2014, 129:130-142.
40. Luo C.L., Li Q.Q., Chen X.P., Zhang X.M., Li L.L., Li B.X., Zhao Z.Q., Tao L.Y. Lipoxin A4 attenuates brain damage and downregulates the production of pro-inflammatory cytokines and phosphorylated mitogen-activated protein kinases in a mouse model of traumatic brain injury. Brain Res. 2013, 1502:1-10.
41. Medeiros R., Kitazawa M., Passos G.F., Baglietto-Vargas D., Cheng D., Cribbs D.H., LaFerla F.M. Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. Am. J. Pathol. 2013, 182:1780-1789.
42. X. Wang, M. Zhu, E. Hjorth, V. Cortes-Toro, H. Eyjolfsdottir, C. Graff, I. Nennesmo, J. Palmblad, M. Eriksdotter, K. Sambamurti, J.M. Fitzgerald, C.N. Serhan, A.C. Granholm, M. Schultzberg, Resolution of inflammation is altered in Alzheimer's disease, Alzheimers Dement. (2014), (Epub ahead of print). http://dx.doi.org/10.1016/j.jalz.2013.12.024.
43. Yao C., Yang D., Wan Z., Wang Z., Liu R., Wu Y., Yao S., Yuan S., Shang Y. Aspirin-triggered lipoxin A4 attenuates lipopolysaccharide induced inflammatory response in primary astrocytes. Int. Immunopharmacol. 2014, 18:85-89.
44. Rockett B.D., Teague H., Harris M., Melton M., Williams J., Wassall S.R., Shaikh S.R. Fish oil increases raft size and membrane order of B cells accompanied by differential effects on function. J. Lipid Res. 2012, 53:674-685.
45. Shaikh S.R. Biophysical and biochemical mechanisms by which dietary N-3 polyunsaturated fatty acids from fish oil disrupt membrane lipid rafts. J. Nutr. Biochem. 2012, 23:101-105.
46. Stillwell W., Shaikh S.R., Zerouga M., Siddiqui R., Wassall S.R. Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod. Nutr. Dev. 2005, 45:559-579.
47. Bassaganya-Riera J., Hontecillas R. CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD. Clin. Nutr. 2006, 25:454-465.
48. Di Nunzio M., Danesi F., Bordoni A. n-3 PUFA as regulators of cardiac gene transcription: a new link between PPAR activation and fatty acid composition. Lipids 2009, 44:1073-1079.
49. Zuniga J., Cancino M., Medina F., Varela P., Vargas R., Tapia G., Videla L.A., Fernandez V. N-3 PUFA supplementation triggers PPAR-alpha activation and PPAR-alpha/NF-kappaB interaction: anti-inflammatory implications in liver ischemia-reperfusion injury. PLoS One 2011, 6:e28502.
50. Oh D.Y., Talukdar S., Bae E.J., Imamura T., Morinaga H., Fan W., Li P., Lu W.J., Watkins S.M., Olefsky J.M. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.
51. Oh D.Y., Olefsky J.M. Omega 3 fatty acids and GPR120. Cell Metab. 2012, 15:564-565.
52. Talukdar S., Olefsky J.M., Osborn O. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol. Sci. 2011, 32:543-550.
53. Kitson A.P., Smith T.L., Marks K.A., Stark K.D. Tissue-specific sex differences in docosahexaenoic acid and Delta6-desaturase in rats fed a standard chow diet. Appl. Physiol. Nutr. Metab. 2012, 37:1200-1211.
54. Stark K.D., Lim S.Y., Salem N. Artificial rearing with docosahexaenoic acid and n-6 docosapentaenoic acid alters rat tissue fatty acid composition. J. Lipid Res. 2007, 48:2471-2477.
55. Chen C.T., Bazinet R.P. beta-oxidation and rapid metabolism, but not uptake regulate brain eicosapentaenoic acid levels. Prostaglandins Leukot. Essent. Fatty Acids 2014.
56. O'Brien J.S., Fillerup D.L., Mead J.F. Quantification and fatty acid and fatty aldehyde composition of ethanolamine, choline, and serine glycerophosphatides in human cerebral grey and white matter. J. Lipid Res. 1964, 5:329-338.
57. O'Brien J.S., Fillerup D.L., Mead J.F. Brain Lipids: I. Quantification and Fatty Acid Composition of Cerebroside Sulfate in Human Cerebral Gray and White Matter. J. Lipid Res. 1964, 5:109-116.
58. Svennerholm L. Distribution and fatty acid composition of phosphoglycerides in normal human brain. J. Lipid Res. 1968, 9:570-579.
59. Farooqui A.A., Horrocks L.A. Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly. Neuroscientist 2006, 12:245-260.
60. Labhsetwar A.P. Effects of prostaglandin F2-alpha on pituitary luteinizing hormone content of pregnant rats: a possible explanation for the luteolytic effect. J. Reprod. Fertil. 1970, 23:155-159.
61. Orczyk G.P., Behrman H.R. Ovulation blockade by aspirin or indomethacin--in vivo evidence for a role of prostaglandin in gonadotrophin secretion. Prostaglandins 1972, 1:3-20.
62. Holmes S.W., Horton E.W. The identification of four prostaglandins in dog brain and their regional distribution in the central nervous system. J. Physiol. 1968, 195:731-741.
63. Coceani F., Puglisi L., Lavers B. Prostaglandins and neuronal activity in spinal and cuneate nucleus. Ann. NY Acad. Sci. 1971, 180:289-301.
64. Betteridge A. Role of Ca2+ and cyclic nucleotides in the control of prostaglandin E production in the rat anterior pituitary gland. Biochem. J. 1980, 186:987-992.
65. Cuttler L., Birkenbach P.A., Szabo M. The effect of age on prostaglandin E2 stimulation of growth hormone release from cultured rat pituitary cells. Endocrinology 1989, 124:661-666.
66. Drouin J., Labrie F. Specificity of the stimulatory effect of prostaglandins on hormone release in rat anterior pituitary cells in culture. Prostaglandins 1976, 11:355-365.
67. MacLeod R.M., Lehmeyer J.E. Release of pituitary growth hormone by prostaglandins and dibutyryl adenosine cyclic 3':5'-monophosphate in the absence of protein synthesis. Proc. Natl. Acad. Sci. USA 1970, 67:1172-1179.
68. Ratner A., Wilson M.C., Peake G.T. Antagonism of prostaglandin-promoted pituitary cyclic AMP accumulation and growth hormone secretion in vitro by 7-oxa-13-prostynoic acid. Prostaglandins 1973, 3:413-419.
69. Takahara J., Mori M., Ofuji N., Hashimoto K., Yamauchi J. Effects of prostaglandin E1 and indomethacin on ACTH, prolactin, GH and LH from rat pituitary in vitro. Endocrinol. Jpn. 1977, 24:97-103.
70. Cooper R.H., McPherson M., Schofield J.G. The effect of prostaglandins on ox pituitary content of adenosine 3':5'-cyclic monophosphate and the release of growth hormone. Biochem. J. 1972, 127:143-154.
71. Hashizume T., Soliman E.B., Kanematsu S. Effects of pituitary adenylate cyclase-activating polypeptide (PACAP), prostaglandin E2 (PGE2) and growth hormone releasing factor (GRF) on the release of growth hormone from cultured bovine anterior pituitary cells in vitro. Domest. Anim. Endocrinol. 1994, 11:331-337.
72. Borgeat P., Labrie F., Garneau P. Characteristics of action of prostaglandins on cyclic AMP accumulation in rat anterior pituitary gland. Can. J. Biochem. 1975, 53:455-460.
73. Hertelendy F., Keay L. Studies on growth homone secretion. VI. Effects of dibutyryl cyclic AMP, prostaglandin E1, and indomethacin on growth and hormone secretion by rat pituitary tumor cells in culture. Prostaglandins 1974, 6:217-225.
74. Rouleau D., Barden N. Inhibition of anterior pituitary prostaglandin-stimulated adenylyl cyclase activity by somatostatin. Can. J. Biochem. 1981, 59:307-310.
75. Zor U., Kaneko T., Schneider H.P., McCann S.M., Field J.B. Further studies of stimulation of anterior pituitary cyclic adenosine 3',5'-monophosphate formation by hypothalamic extract and prostaglandins. J. Biol. Chem. 1970, 245:2883-2888.
76. Bilezikjian L.M., Vale W.W. Stimulation of adenosine 3',5'-monophosphate production by growth hormone-releasing factor and its inhibition by somatostatin in anterior pituitary cells in vitro. Endocrinology 1983, 113:1726-1731.
77. Kasting N.W., Martin J.B. Endogenous prostaglandins affect growth hormone and thyrotropin release at a hypothalamic, not a pituitary level. Neuroendocrinology 1984, 39:201-205.
78. Harms P.G., Ojeda S.R., McCann S.M. Prostaglandin-induced release of pituitary gonadotropins: central nervous system and pituitary sites of action. Endocrinology 1974, 94:1459-1464.
79. Ojeda S.R., Jameson H.E., McCann S.M. Effects of indomethacin and prostaglandin injections on plasma prolactin and growth hormone levels in rats. Endocrinology 1978, 102:531-539.
80. Betteridge A., Wallis M. Stimulation of anterior pituitary prostaglandin E content and somatotropin (growth hormone) synthesis by phospholipase A. Biochem. J. 1978, 176:319-323.
81. Wilson D.E., Phillips C., Levine R.A. Inhibition of gastric secretion in man by prostaglandin A. Gastroenterology 1971, 61:201-206.
82. Betteridge A., Wallis M. Involvement of prostaglandins in the inhibition of growth hormone production in cultured pituitary cells by insulin. J. Endocrinol. 1979, 80:239-248.
83. Betteridge A., Wallis M. Role of prostaglandins and adenosine 3':5'-cyclic monophosphate in the control by insulin of growth-hormone synthesis in vitro. Biochem. Soc. Trans. 1977, 5:224-226.
84. Vijayakumar A., Novosyadlyy R., Wu Y., Yakar S., LeRoith D. Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm. IGF Res. 2010, 20:1-7.
85. Vijayakumar A., Yakar S., Leroith D. The intricate role of growth hormone in metabolism. Front. Endocrinol. (Lausanne) 2011, 2:32.
86. Melmed S. Pituitary 2010, Academic Press, Saint Louis, MO, USA. Third ed.
87. Vermouth N.T., Deis R.P. Prolactin release induced by prostaglandin F2 in pregnant rats. Nat. New Biol. 1972, 238:248-250.
88. Sato T., Jyujo T. Correlation between cyclic AMP and LH release following prostaglandin E2 administration. Prostaglandins 1976, 12:1083-1091.
89. Burton N., Carlile S., Jubiz W. Prostaglandin F2alpha (PGF2alpha) and prolactin secretion in rats. Prostaglandins 1975, 10:667-674.
90. Yue D.K., Smith I.D., Turtle J.R., Shearman R.P. Effect of prostaglandin F2 alpha on the secretion of human prolactin. Prostaglandins 1974, 8:387-395.
91. Harms P.G., Ojeda S.R., McCann S.M. Prostaglandin involvement in hypothalamic control of gonadotropin and prolactin release. Science 1973, 181:760-761.
92. Ojeda S.R., Harms P.G., McCann S.M. Central effect of prostaglandin E1 (PGE1) on prolactin release. Endocrinology 1974, 95:613-618.
93. Ojeda S.R., Harms P.G., McCann S.M. Possible role of cyclic AMP and prostaglandin E1 in the dopaminergic control of prolactin release. Endocrinology 1974, 95:1694-1703.
94. Warberg J., Eskay R.L., Porter J.C. Prostaglandin-induced release of anterior pituitary hormones: structure-activity relationships. Endocrinology 1976, 98:1135-1141.
95. Chu Y.C., Tsou M.Y., Pan J.T. Prostaglandins play an important role in diurnal changes of tuberoinfundibular dopaminergic neuronal activity and prolactin secretion in ovariectomized, estrogen-treated rats. Brain Res. Bull. 2001, 55:87-93.
96. Ratner A., Wilson M.C., Srivastava L., Peake G.T. Stimulatory effects of prostaglandin e-1 on rat anterior pituitary cyclic AMP and luteinizing hormone release. Prostaglandins 1974, 5:165-171.
97. Sato T., Jyujo T., Iesaka T., Ishikawa J., Igarashi M. Follicle stimulating hormone and prolactin release induced by prostaglandins in rat. Prostaglandins 1974, 5:483-490.
98. Sato T., Taya K., Jyujyo T., Hirono M., Igarashi M. The stimulatory effect of prostaglandins on luteinizing hormone release. Am. J. Obstet. Gynecol. 1974, 118:875-876.
99. Chobsieng P., Naor Z., Koch Y., Zor U., Lindner H.R. Stimulatory effect of prostaglandin E2 on LH release in the rat: evidence for hypothalamic site of action. Neuroendocrinology 1975, 17:12-17.
100. Ratner A. Stimulation of luteinizing hormone release in vitro by dibutyryl-cyclic-AMP and theophylline. Life Sci. I 1970, 9:1221-1226.
101. Kragt C.L., Bergstrom K.K., Voogt J.L. Interactions of prostaglandin E1 (PGE1) and LRH on anterior pituitary function. Prostaglandins 1975, 10:833-851.
102. Naor Z., Koch Y., Chobsieng P., Zor U. Pituitary cyclic AMP production and mechanism of luteinizing hormone release. FEBS Lett. 1975, 58:318-321.
103. Sundberg D.K., Fawcett C.P., Illner P., McCann S.M. The effect of various prostaglandins and a prostaglandin synthetase inhibitor on rat anterior pituitary cyclic AMP levels and hormone release in vitro (38475). Proc. Soc. Exp. Biol. Med. 1975, 148:54-59.
104. Emons G., Thiessen S., Gethmann U. Prostaglandins have no effect on spontaneous and gonadotrophin-releasing hormone stimulated luteinizing hormone release in cultured rat pituitary cells. Arch. Gynecol. 1984, 234:263-268.
105. Makino T. Study on the intracellular mechanism of LH release in the anterior pituitary. Am. J. Obstet. Gynecol. 1973, 115:606-614.
106. Sato T., Hirono M., Jyujo T., Iesaka T., Taya K. Direct action of prostaglandins on the rat pituitary. Endocrinology 1975, 96:45-49.
107. Spies H.G., Norman R.L. Luteinizing hormone release and ovulation induced by the intraventricular infusion of prostaglandin E1 into pentobarbital-blocked rats. Prostaglandins 1973, 4:131-141.
108. Brown C.G., Poyser N.L. Studies on the control of prostaglandin production by the hypothalamus in relation to LH release in the rat. J. Endocrinol. 1984, 103:155-164.
109. Cardinali D.P., Fernandez Pardal J., Gimeno M.F., Gimeno A.L. Effects of estradiol on norepinephrine and prostaglandin efflux in medial basal hypothalamus of ovariectomized rats. J. Neural Transm. 1982, 53:39-47.
110. Cardinali D.P., Ritta M.N. The role of prostaglandins in neuroendocrine junctions: studies in the pineal gland and the hypothalamus. Neuroendocrinology 1983, 36:152-160.
111. Kim K., Ramirez V.D. Effects of prostaglandin E2, forskolin and cholera toxin on cAMP production and in vitro LH-RH release from the rat hypothalamus. Brain Res. 1986, 386:258-265.
112. Labhsetwar A.P., Zolovick A. Hypothalamic interaction between prostaglandins and catecholamines in promoting gonadotrophin secretion for ovulation. Nat. New Biol. 1973, 246:55-56.
113. Sato T., Jyujo T., Hirono M., Iesaka T. Effects of indomethacin, an inhibitor of prostaglandin synthesis, on the hypothalamic-pituitary system in rats. J. Endocrinol. 1975, 64:395-396.
114. Fraschini F., Mess B., Piva F., Martini L. Brain receptors sensitive to indole compounds: function in control of luteinizing hormone secretion. Science 1968, 159:1104-1105.
115. Gimeno M.F., Landa A., Sterin-Speziale N., Cardinali D.P., Gimeno A.L. Melatonin blocks in vitro generation of prostaglandin by the uterus and hypothalamus. Eur. J. Pharmacol. 1980, 62:309-317.
116. Ojeda S.R., Harms P.G., McCann S.M. Effect of inhibitors of prostaglandin synthesis on gonadotropin release in the rat. Endocrinology 1975, 97:843-854.
117. McCann S.M., Ojeda S.R., Harms P.G., Wheaton J.E., Sundberg D.K., Fawcett C.P. Role of prostaglandins (PGs) in the control of adenohypophyseal hormone secretion. Curr. Top. Mol. Endocrinol. 1976, 3:21-35.
118. Bettahi I., Guerrero J.M., Reiter R.J., Osuna C. Physiological concentrations of melatonin inhibit the norepinephrine-induced activation of prostaglandin E2 and cyclic AMP production in rat hypothalamus: a mechanism involving inhibiton of nitric oxide synthase. J. Pineal Res. 1998, 25:34-40.
119. Kilic A., Durmus M.S., Unuvar E., Yildiz I., Aydin B.K., Ucar A., Bundak R., Bas F., Darendeliler F., Oguz F., Sidal M., Yekeler E. Clinical and laboratory characteristics of children referred for early puberty: preponderance in 7-8 years of age. J. Clin. Res. Pediatr. Endocrinol. 2012, 4:208-212.
120. Zung A., Burundukov E., Ulman M., Glaser T., Rosenberg M., Chen M., Zadik Z. The diagnostic value of first-voided urinary LH compared with GnRH-stimulated gonadotropins in differentiating slowly-progressive from rapidly Progressive-precocious puberty in girls. Eur. J. Endocrinol. 2014.
121. Poretsky L., Cataldo N.A., Rosenwaks Z., Giudice L.C. The insulin-related ovarian regulatory system in health and disease. Endocr. Rev. 1999, 20:535-582.
122. Gambineri A., Pelusi C., Vicennati V., Pagotto U., Pasquali R. Obesity and the polycystic ovary syndrome. Int. J. Obes. Relat. Metab. Disord. 2002, 26:883-896.
123. McCartney C.R., Prendergast K.A., Chhabra S., Eagleson C.A., Yoo R., Chang R.J., Foster C.M., Marshall J.C. The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J. Clin. Endocrinol. Metab. 2006, 91:1714-1722.
124. Tal E., Szabo M., Burke G. TRH and prostaglandin action on rat anterior pituitary: dissociation between cyclic AMP levels and TSH release. Prostaglandins 1974, 5:175-182.
125. Valenti G., Ceda G.P., Tarditi E., Banchini A., Vescovi P.P., Chiodera P., Coiro V., Butturini U. Possible interaction of PGF2 alpha with hypothalamus-pituitary-thyroid axis in man. Prostaglandins 1976, 11:303-317.
126. Eskay R.L., Warberg J., Mical R.S., Porter J.C. Prostaglandin E2-induced release of LHRH into hypophysial portal blood(1). Endocrinology 1975, 97:816-824.
127. Brown M.R., Hedge G.A. In vivo effects of prostaglandins on TRH-induced TSH secretion. Endocrinology 1974, 95:1392-1397.
128. Ruhla S., Weickert M.O., Arafat A.M., Osterhoff M., Isken F., Spranger J., Schofl C., Pfeiffer A.F., Mohlig M. A high normal TSH is associated with the metabolic syndrome. Clin. Endocrinol. (Oxf) 2010, 72:696-701.
129. Muscogiuri G., Sorice G.P., Mezza T., Prioletta A., Lassandro A.P., Pirronti T., Della Casa S., Pontecorvi A., Giaccari A., High-normal TSH values in obesity: is it insulin resistance or adipose tissue's guilt?. Obesity (Silver Spring) 2013, 21:101-106.
130. Ford M.J., Cameron E.H., Ratcliffe W.A., Horn D.B., Toft A.D., Munro J.F. TSH response to TRH in substantial obesity. Int. J. Obes. 1980, 4:121-125.
131. Donders S.H., Pieters G.F., Heevel J.G., Ross H.A., Smals A.G., Kloppenborg P.W. Disparity of thyrotropin (TSH) and prolactin responses to TSH-releasing hormone in obesity. J. Clin. Endocrinol. Metab. 1985, 61:56-59.
132. Coiro V., Volpi R., Capretti L., Speroni G., Pilla S., Cataldo S., Bianconcini M., Bazzani E., Chiodera P. Effect of dexamethasone on TSH secretion induced by TRH in human obesity. J. Investig. Med. 2001, 49:330-334.
133. Hedge G.A. Hypothalamic and pituitary effects of prostaglandins on ACTH secretion. Prostaglandins 1976, 11:293-301.
134. Kehrer P., Turnill D., Dayer J.M., Muller A.F., Gaillard R.C. Human recombinant interleukin-1 beta and -alpha, but not recombinant tumor necrosis factor alpha stimulate ACTH release from rat anterior pituitary cells in vitro in a prostaglandin E2 and cAMP independent manner. Neuroendocrinology 1988, 48:160-166.
135. Deauseault D., Giroux D., Wood C.E. Ontogeny of immunoreactive prostaglandin endoperoxide synthase isoforms in ovine fetal pituitary, hypothalamus and brainstem. Neuroendocrinology 2000, 71:287-291.
136. Brooks A.N., Gibson F. Prostaglandin E2 enhances AVP-stimulated but not CRF-stimulated ACTH secretion from cultured fetal sheep pituitary cells. J. Endocrinol. 1992, 132:33-38.
137. Okajima T., Heldt R., Hertting G. Functional compartmentalization of arginine-vasopressin-activated cyclic AMP in anterior pituitary gland: the presence of a compartment activated by prostaglandin E2. Life Sci. 1986, 38:1143-1149.
138. Bugajski J., Gadek-Michalska A., Bugajski A.J. Nitric oxide and prostaglandin systems in the stimulation of hypothalamic-pituitary-adrenal axis by neurotransmitters and neurohormones. J. Physiol. Pharmacol. 2004, 55:679-703.
139. Reimsnider S.K., Wood C.E. Co-localisation of prostaglandin endoperoxide synthase and immunoreactive adrenocorticotrophic hormone in ovine foetal pituitary. J. Endocrinol. 2004, 180:303-310.
140. Navarra P., Tsagarakis S., Faria M.S., Rees L.H., Besser G.M., Grossman A.B. Interleukins-1 and -6 stimulate the release of corticotropin-releasing hormone-41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase pathway. Endocrinology 1991, 128:37-44.
141. Cartmell T., Luheshi G.N., Hopkins S.J., Rothwell N.J., Poole S. Role of endogenous interleukin-1 receptor antagonist in regulating fever induced by localised inflammation in the rat. J. Physiol. 2001, 531:171-180.
142. Grinevich V., Ma X.M., Herman J.P., Jezova D., Akmayev I., Aguilera G. Effect of repeated lipopolysaccharide administration on tissue cytokine expression and hypothalamic-pituitary-adrenal axis activity in rats. J. Neuroendocrinol. 2001, 13:711-723.
143. Schmidt E.D., Aguilera G., Binnekade R., Tilders F.J. Single administration of interleukin-1 increased corticotropin releasing hormone and corticotropin releasing hormone-receptor mRNA in the hypothalamic paraventricular nucleus which paralleled long-lasting (weeks) sensitization to emotional stressors. Neuroscience 2003, 116:275-283.
144. Shintani F., Nakaki T., Kanba S., Sato K., Yagi G., Shiozawa M., Aiso S., Kato R., Asai M. Involvement of interleukin-1 in immobilization stress-induced increase in plasma adrenocorticotropic hormone and in release of hypothalamic monoamines in the rat. J. Neurosci. 1995, 15:1961-1970.
145. Watanobe H., Takebe K. Effects of intravenous administration of interleukin-1-beta on the release of prostaglandin E2, corticotropin-releasing factor, and arginine vasopressin in several hypothalamic areas of freely moving rats: estimation by push-pull perfusion. Neuroendocrinology 1994, 60:8-15.
146. Milton N.G., Self C.H., Hillhouse E.W. Effects of pyrogenic immunomodulators on the release of corticotrophin-releasing factor-41 and prostaglandin E2 from the intact rat hypothalamus in vitro. Br. J. Pharmacol. 1993, 109:88-93.
147. Buller K.M., Xu Y., Day T.A. Indomethacin attenuates oxytocin and hypothalamic-pituitary-adrenal axis responses to systemic interleukin-1 beta. J. Neuroendocrinol. 1998, 10:519-528.
148. Quan N., He L., Lai W. Endothelial activation is an intermediate step for peripheral lipopolysaccharide induced activation of paraventricular nucleus. Brain Res. Bull. 2003, 59:447-452.
149. Konsman J.P., Vigues S., Mackerlova L., Bristow A., Blomqvist A. Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J. Comp. Neurol. 2004, 472:113-129.
150. Breder C.D., Saper C.B. Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide. Brain Res. 1996, 713:64-69.
151. Cao C., Matsumura K., Yamagata K., Watanabe Y. Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1 beta: a possible site of prostaglandin synthesis responsible for fever. Brain Res. 1996, 733:263-272.
152. Engblom D., Saha S., Engstrom L., Westman M., Audoly L.P., Jakobsson P.J., Blomqvist A. Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. Nat. Neurosci. 2003, 6:1137-1138.
153. Matsuoka Y., Furuyashiki T., Bito H., Ushikubi F., Tanaka Y., Kobayashi T., Muro S., Satoh N., Kayahara T., Higashi M., Mizoguchi A., Shichi H., Fukuda Y., Nakao K., Narumiya S. Impaired adrenocorticotropic hormone response to bacterial endotoxin in mice deficient in prostaglandin E receptor EP1 and EP3 subtypes. Proc. Natl. Acad. Sci. USA 2003, 100:4132-4137.
154. Russo-Marie F., Duval D. Mechanism of action of glucocortioids on prostaglandin secretion. Prostaglandin Synthetase Inhibitors: New Clinical Applications 1980, 13-29. Alan R. Liss, Inc., New York. P. Ramwell (Ed.).
155. Lewis G.D., Campbell W.B., Johnson A.R. Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells. Endocrinology 1986, 119:62-69.
156. Thoren M., Stenfors C., Aperia B., Mathe A.A. Hypothalamic-pituitary-adrenal axis interaction with prostaglandins. Prog. Neuropsychopharmacol. Biol. Psychiatry 1990, 14:319-326.
157. Turnbull A.V., Rivier C. Corticotropin-releasing factor, vasopressin, and prostaglandins mediate, and nitric oxide restrains, the hypothalamic-pituitary-adrenal response to acute local inflammation in the rat. Endocrinology 1996, 137:455-463.
158. Elander L., Engstrom L., Ruud J., Mackerlova L., Jakobsson P.J., Engblom D., Nilsberth C., Blomqvist A. Inducible prostaglandin E2 synthesis interacts in a temporally supplementary sequence with constitutive prostaglandin-synthesizing enzymes in creating the hypothalamic-pituitary-adrenal axis response to immune challenge. J. Neurosci. 2009, 29:1404-1413.
159. Costa A., Poma A., Martignoni E., Nappi G., Ur E., Grossman A. Stimulation of corticotrophin-releasing hormone release by the obese (ob) gene product, leptin, from hypothalamic explants. Neuroreport 1997, 8:1131-1134.
160. Raber J., Chen S., Mucke L., Feng L. Corticotropin-releasing factor and adrenocorticotrophic hormone as potential central mediators of OB effects. J. Biol. Chem. 1997, 272:15057-15060.
161. Brunetti L., Orlando G., Michelotto B., Ragazzoni E., Vacca M. Leptin stimulates prostaglandin E2 and F2alpha, but not nitric oxide production in neonatal rat hypothalamus. Eur. J. Pharmacol. 1999, 369:299-304.
162. Krahn D.D., Gosnell B.A., Levine A.S., Morley J.E. Behavioral effects of corticotropin-releasing factor: localization and characterization of central effects. Brain Res. 1988, 443:63-69.
163. Rothwell N.J. Central effects of CRF on metabolism and energy balance. Neurosci. Biobehav. Rev. 1990, 14:263-271.
164. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
165. Bojanowska E., Guzek J.W. Prostaglandin F2 alpha stimulates vasopressin and oxytocin release from isolated rat neurointermediate lobe. Exp. Clin. Endocrinol. 1989, 94:375-382.
166. Hashimoto H., Noto T., Nakajima T. Effects of prostaglandin E2 and D2 on the release of vasopressin and oxytocin. Prostaglandins Leukot. Essent. Fatty Acids 1989, 36:9-14.
167. Negro-Vilar A., Snyder G.D., Falck J.R., Manna S., Chacos N., Capdevila J. Involvement of eicosanoids in release of oxytocin and vasopressin from the neural lobe of the rat pituitary. Endocrinology 1985, 116:2663-2668.
168. Knepel W., Nutto D., Vlaskovska M., Kittel C. Inhibition by prostaglandin E2 of the release of vasopressin and beta-endorphin from rat pituitary neurointermediate lobe or medial basal hypothalamus in vitro. J. Endocrinol. 1985, 106:189-195.
169. Brooks D.P., Share L., Crofton J.T. Role of brain prostaglandins in the control of vasopressin secretion in the conscious rat. Endocrinology 1986, 118:1716-1722.
170. Hoffman W.E., Schmid P.G. Cardiovascular and antidiuretic effects of central prostaglandin E2. J. Physiol. 1979, 288:159-169.
171. Parrott R.F., Vellucci S.V., Forsling M.L., Goode J.A. Hyperthermic and endocrine effects of intravenous prostaglandin administration in the pig. Domest. Anim. Endocrinol. 1995, 12:197-205.
172. Puurunen J., Leppaluoto J. Centrally administered PGE2 inhibits gastric secretion in the rat by releasing vasopressin. Eur. J. Pharmacol. 1984, 104:145-150.
173. Fujimoto S. The effect of prostaglandin E2 microinjected into the rat hypothalamus on urinary excretion of water and sodium. Br. J. Pharmacol. 1980, 70:415-417.
174. Puurunen J. Central gastric antisecretory action of prostaglandin E2: the involvement of the pituitary gland. J. Pharmacol. Exp. Ther. 1984, 231:713-716.
175. Bojanowska E., Guzek J.W. Inhibition of prostaglandin synthesis and the release of vasopressin and oxytocin from the rat neurohypophysis: in vitro studies. Exp. Clin. Endocrinol. 1991, 98:213-221.
176. Kasting N.W. Indomethacin, an antipyretic drug, prevents the endotoxin-induced and potentiates the hemorrhage-induced oxytocin release into the plasma of the male rat. Neuroendocrinology 1986, 42:285-288.
177. Naito Y., Fukata J., Shindo K., Ebisui O., Murakami N., Tominaga T., Nakai Y., Mori K., Kasting N.W., Imura H. Effects of interleukins on plasma arginine vasopressin and oxytocin levels in conscious, freely moving rats. Biochem. Biophys. Res. Commun. 1991, 174:1189-1195.
178. Summy-Long J.Y., Bui V., Gestl S., Kadekaro M. Nitric oxide, interleukin and prostaglandin interactions affecting the magnocellular system. Brain Res. 2002, 940:10-20.
179. Yasin S.A., Costa A., Forsling M.L., Grossman A. Interleukin-1 beta and interleukin-6 stimulate neurohypophysial hormone release in vitro. J. Neuroendocrinol. 1994, 6:179-184.
180. Knigge U., Kjaer A., Kristoffersen U., Madsen K., Toftegaard C., Jorgensen H., Warberg J. Histamine and prostaglandin interaction in regulation of oxytocin and vasopressin secretion. J. Neuroendocrinol. 2003, 15:940-945.
181. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol. 2004, 63:901-910.
182. Hein A.M., O'Banion M.K. Neuroinflammation and memory: the role of prostaglandins. Mol. Neurobiol. 2009, 40:15-32.
183. Xiang Y., Chen L., Liu H., Liu X., Wei X., Sun B., Wang T., Zhang X. Inhibition of sPLA(2)-IIA prevents LPS-induced neuroinflammation by suppressing ERK1/2-cPLA(2)alpha pathway in mice cerebral cortex. PLoS One 2013, 8:e77909.
184. Brenneis C., Coste O., Altenrath K., Angioni C., Schmidt H., Schuh C.D., Zhang D.D., Henke M., Weigert A., Brune B., Rubin B., Nusing R., Scholich K., Geisslinger G. Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation. J. Biol. Chem. 2011, 286:2331-2342.
185. Begg D.P., Sinclair A.J., Weisinger R.S. Thirst deficits in aged rats are reversed by dietary omega-3 fatty acid supplementation. Neurobiol. Aging 2012, 33:2422-2430.
186. Liu Y., Chen F., Li Q., Odle J., Lin X., Zhu H., Pi D., Hou Y., Hong Y., Shi H. Fish oil alleviates activation of the hypothalamic-pituitary-adrenal axis associated with inhibition of TLR4 and NOD signaling pathways in weaned piglets after a lipopolysaccharide challenge. J. Nutr. 2013, 143:1799-1807.
187. Levant B. N-3 (omega-3) polyunsaturated Fatty acids in the pathophysiology and treatment of depression: pre-clinical evidence. CNS Neurol. Disord. Drug Targets 2013, 12:450-459.
188. Jiang L.H., Liang Q.Y., Shi Y. Pure docosahexaenoic acid can improve depression behaviors and affect HPA axis in mice. Eur. Rev. Med. Pharmacol. Sci. 2012, 16:1765-1773.
189. Chen H.F., Su H.M. Exposure to a maternal n-3 fatty acid-deficient diet during brain development provokes excessive hypothalamic-pituitary-adrenal axis responses to stress and behavioral indices of depression and anxiety in male rat offspring later in life. J. Nutr. Biochem. 2013, 24:70-80.
190. Li D., Weisinger H.S., Weisinger R.S., Mathai M., Armitage J.A., Vingrys A.J., Sinclair A.J. Omega 6 to omega 3 fatty acid imbalance early in life leads to persistent reductions in DHA levels in glycerophospholipids in rat hypothalamus even after long-term omega 3 fatty acid repletion. Prostaglandins Leukot. Essent. Fatty Acids 2006, 74:391-399.
191. Armitage J.A., Pearce A.D., Sinclair A.J., Vingrys A.J., Weisinger R.S., Weisinger H.S. Increased blood pressure later in life may be associated with perinatal n-3 fatty acid deficiency. Lipids 2003, 38:459-464.
192. Weisinger H.S., Armitage J.A., Sinclair A.J., Vingrys A.J., Burns P.L., Weisinger R.S. Perinatal omega-3 fatty acid deficiency affects blood pressure later in life. Nat. Med. 2001, 7:258-259.